zika
viru
zikv
mosquitoborn
flaviviru
isol
blood
sentinel
rhesu
monkey
uganda
april
although
serolog
data
indic
high
preval
zikv
africa
fourteen
case
zikv
mild
ill
report
african
contin
southeast
asia
howev
chang
outbreak
yap
island
estim
popul
affect
moreov
epidem
french
polynesia
neurolog
complic
syndrom
gb
newborn
microcephali
manifest
asid
typic
flulik
symptom
shortli
thereaft
follow
increas
microcephali
case
brazil
zikv
declar
public
health
emerg
intern
concern
pheic
like
flavivirus
zikv
envelop
viru
possess
posit
singlestrand
rna
genom
approxim
kb
genom
encod
viral
polyprotein
process
three
c
envelop
e
precursor
membran
prm
seven
nonstructur
protein
zikv
life
cycl
yet
fulli
unveil
expect
life
cycl
concur
flavivirus
viral
life
cycl
initi
interact
viral
envelop
protein
host
cell
receptor
adhesionentri
factor
dcsign
axl
nevertheless
conflict
data
relev
axl
primari
receptor
zikv
entri
intern
via
receptormedi
endocytosi
assum
acidif
late
endosom
also
term
multivesicular
bodi
mvb
promot
structur
chang
viral
envelop
allow
fusion
endosom
membran
envelop
lead
releas
viral
nucleocapsid
cytoplasm
consequ
disassembl
capsid
uncoat
viral
rna
genom
rna
translat
replic
newli
synthes
immatur
viral
particl
assembl
conduct
secretori
pathway
immatur
form
pr
peptid
cover
approxim
amino
acid
fusion
loop
envelop
protein
thu
prevent
prematur
fusion
within
cell
transgolgi
network
tgn
viral
particl
undergo
matur
result
structur
modif
induc
low
ph
allow
cleavag
prm
furinlik
proteas
expos
fusion
loop
lastli
infecti
viral
particl
exit
cell
exocytosi
pr
fragment
dissoci
virion
due
neutral
ph
extracellular
environ
besid
bite
infect
mosquito
aed
aegypti
aed
albopictu
zikv
infect
occur
perinat
transmiss
sexual
contact
blood
transfus
sinc
vaccin
specif
antivir
drug
avail
zikv
understand
viral
life
cycl
find
way
control
infect
becom
urgent
although
zikv
life
cycl
often
describ
resembl
life
cycl
flaviviru
member
varieti
open
question
respect
viral
life
cycl
still
exist
light
import
compart
zikv
life
cycl
investig
firstli
acidif
late
endosomesmvb
tgn
compart
impair
highli
select
inhibitor
vacuolar
hatpas
vatpas
bafilomycin
relev
acidif
endosom
compart
zikv
entri
previous
studi
huh
cell
cortes
et
al
cell
cao
et
al
recent
vero
cell
persaud
et
al
data
cell
show
one
hand
bafilomycin
abl
fulli
inhibit
zikv
entri
hand
interfer
viral
matur
concern
cell
bafilomycin
decreas
zikv
entri
second
part
studi
function
late
endosom
lysosom
hinder
amphipath
steroid
drug
inhibit
intracellular
traffick
cholesterol
lipid
direct
inhibit
type
c
protein
result
cholesterol
accumul
late
endosomesmvb
lysosom
lead
impair
function
sever
report
show
inhibit
crucial
step
dengu
viru
hepat
c
viru
ebola
viru
felin
coronaviru
life
cycl
howev
studi
perform
investig
impact
zikv
infect
work
provid
insight
zikv
life
cycl
elucid
crucial
step
viral
entri
releas
human
epitheli
lung
carcinoma
cell
african
green
monkey
kidney
cell
vero
human
neuroblastoma
cell
grown
dulbecco
modifi
eagl
medium
dmem
high
glucos
biowest
franc
supplement
fetal
bovin
serum
superior
biochrom
gmbh
berlin
germani
mm
lglutamin
biochrom
gmbh
berlin
germani
uml
penicillin
streptomycin
paulehrlichinstitut
facil
langen
germani
humidifi
incub
passag
adher
cell
perform
trypsin
three
time
week
cell
infect
either
french
polynesia
uganda
strain
zikv
kindli
provid
dr
didier
musso
institut
loui
tahiti
european
viru
archiv
respect
studi
multipl
infect
moi
chosen
infect
cell
h
inoculum
remov
wash
cell
pb
indic
time
cell
cultur
supernat
collect
store
cell
wash
pb
lyse
infect
cell
treat
nm
bafilomycin
sigmaaldrich
st
loui
usa
either
h
pre
post
infect
bafilomycin
perman
present
renew
hour
postinfect
hpi
assur
constant
level
substanc
cell
cell
preinfect
treatment
appli
investig
effect
bafilomycin
viral
matur
infect
cell
treat
either
nm
bafilomycin
respect
amount
vehicl
control
dmso
genaxxon
bioscienc
gmbh
ulm
germani
last
h
harvest
cell
cell
cultur
supernat
harvest
hpi
investig
effect
furinlik
proteas
viral
matur
infect
cell
treat
furin
inhibitor
sigmaaldrich
st
loui
usa
last
h
harvest
modul
autophagi
accomplish
mm
selleckchem
houston
tx
usa
nm
rapamycin
selleckchem
houston
usa
cell
treat
h
post
infect
treatment
renew
hpi
assur
constant
level
compound
cell
treatment
infect
cell
sigmaaldrich
st
loui
usa
start
h
post
infect
also
continu
present
renew
hpi
assur
constant
level
substanc
cell
investig
effect
viral
entri
cell
pretreat
h
infect
h
either
moi
titrat
viru
perform
plaqu
form
assay
purpos
vero
cell
infect
serial
dilut
either
clear
cell
lysat
supernat
cell
lysat
achiev
three
cycl
cell
suspens
follow
centrifug
step
g
hpi
inoculum
remov
agaros
lonza
basel
switzerland
dmem
complet
pour
care
cell
solidif
agaros
overlay
carri
room
temperatur
min
visual
plaqu
perform
describ
elgner
et
al
viru
titer
express
plaqu
form
unit
per
ml
pfuml
cell
lyse
peqgold
trifast
peqlab
biotechnologi
gmbh
erlangen
germani
total
intracellular
rna
isol
accord
manufactur
instruct
dna
digest
rnasefre
dnase
promega
fitchburg
usa
total
rna
transcrib
cdna
random
hexam
primer
revertaid
h
minu
revers
transcriptas
thermo
fischer
scientif
waltham
usa
specifi
manufactur
extracellular
rna
extract
use
qiaamp
viral
rna
mini
kit
qiagen
hilden
germani
follow
manufactur
instruct
quantif
intracellular
zikv
transcript
perform
realtim
rt
pcr
use
maxima
sybr
green
qpcr
kit
thermo
fischer
scientif
waltham
usa
follow
primer
zikvfwd
agatcccggctgaaacactg
zikvrev
ttgcaaggtccatctgtccc
aaagctgtcatcgtgaagaac
gctgctactttgcgggggtag
housekeep
gene
human
ribosom
protein
util
normal
amount
intracellular
zikv
transcript
quantif
extracellular
zikv
rna
perform
use
lightmix
modular
zika
viru
assay
kit
tib
molbiol
germani
togeth
multiplex
rna
viru
master
kit
roch
basel
switzerland
quantif
obtain
system
roch
basel
switzerland
accord
manufactur
instruct
determin
cell
viabil
bafilomycin
furin
inhibitor
treatment
accomplish
use
cell
viabil
reagent
thermo
fischer
scientif
waltham
usa
describ
manufactur
cell
seed
flatbottom
polystyren
plate
greiner
frickenhausen
germani
densiti
cell
per
well
respect
treat
differ
concentr
compound
desir
time
triton
sigmaaldrich
st
loui
usa
includ
posit
control
fluoresc
reagent
measur
micropl
reader
infinit
tecan
basel
switzerland
h
incub
linear
pflzikvrluc
kindli
provid
scott
c
weaver
institut
human
infect
immun
univers
texa
medic
branch
galveston
texa
usa
achiev
incub
u
clai
thermo
fischer
scientif
waltham
usa
h
transcript
perform
linear
plasmid
use
standard
rna
ivt
kit
biozym
hessisch
oldendorf
germani
h
subsequ
rnasefre
dnase
treatment
extract
rna
dissolv
depc
water
frozen
aliquot
cell
harvest
confluenc
wash
twice
icecold
pb
dilut
final
concentr
cellsml
electropor
vitro
transcrib
rna
mix
cell
suspens
ad
electropor
cuvett
mm
vwr
darmstadt
germani
immedi
puls
use
gene
pulser
biorad
dreieich
germani
adjust
deliv
one
puls
v
incub
min
room
temperatur
electropor
cell
dilut
ml
dmem
complet
seed
appropri
cultur
dish
h
postelectropor
medium
chang
luciferas
reportergen
assay
stabl
zikvrluc
produc
cell
seed
polystyren
plate
contain
cell
per
well
greiner
frickenhausen
germani
code
sequenc
renilla
luciferas
report
insert
zikv
genom
zikv
strain
genbank
number
translat
polyprotein
luciferas
releas
polyprotein
process
indic
treatment
cell
lyse
lysi
buffer
pjk
kleinbittersdorf
germani
scrape
plate
transfer
eppendorf
tube
centrifug
min
g
determin
luciferas
activ
perform
use
gaussia
glowjuic
kit
pjk
kleinbittersdorf
germani
accord
manufactur
instruct
shortli
lysat
analyz
autom
addit
gaussia
glowjuic
ctz
subsequ
determin
chemiluminesc
orion
ii
micropl
luminomet
titertek
pforzheim
germani
luciferas
level
refer
protein
concentr
appropri
lysat
protein
amount
measur
use
bradford
assay
specifi
manufactur
bradford
reagent
thermoscientif
braunschweig
germani
sampl
prepar
separ
protein
perform
describ
glitscher
et
al
separ
sdspage
protein
transfer
onto
methanolactiv
polyvinyliden
difluorid
pvdf
carl
roth
karlsruh
germani
membran
use
semidri
blot
chamber
current
protein
interest
detect
antizikv
biofront
technolog
tallahasse
usa
progen
biotechnik
gmbh
heidelberg
germani
bd
bioscienc
franklin
lake
usa
biozol
diagnostica
vertrieb
gmbh
echnig
germani
antizikv
e
kindli
provid
sami
akhra
paulehrlichinstitut
germani
antizikv
prm
genetex
irvin
usa
sigmaaldrich
st
loui
usa
detect
use
load
control
secondari
antibodi
either
horseradish
peroxidas
hrp
coupl
antibodi
ge
healthcar
littl
chalfont
unit
kingdom
fluorophorecoupl
antibodi
licor
bioscienc
lincoln
usa
util
accord
manufactur
instruct
protein
band
detect
luminata
fort
western
hrp
substrat
merck
millipor
darmstadt
germani
scientif
imag
film
ge
healthcar
littl
chalfont
unit
kingdom
altern
use
licor
odyssey
infrar
imag
system
licor
bioscienc
lincoln
usa
densitometr
quantif
desir
protein
accomplish
imag
studio
lite
softwar
licor
bioscienc
lincoln
usa
two
protocol
use
depend
primari
antibodi
fluoresc
dye
util
cell
grown
coverslip
desir
time
fix
either
formaldehyd
pb
icecold
ethanol
aceton
min
room
temperatur
respect
case
formaldehyd
fixat
cell
permeabil
block
describ
elgner
et
al
cell
incub
antiflaviviru
group
antigen
antibodi
clone
merck
millipor
darmstadt
germani
antizikv
biofront
technolog
tallahasse
usa
progen
biotechnik
gmbh
heidelberg
germani
antilamin
santa
cruz
biotechnolog
dalla
usa
afterward
cell
incub
antimous
iggalexa
thermo
fisher
scientif
waltham
usa
antiguinea
pig
jackson
immunoresearch
west
grove
usa
antirabbit
jackson
immunoresearch
west
grove
usa
togeth
secondari
antibodi
cell
incub
filipin
complex
sigmaaldrich
st
loui
usa
dapi
carl
roth
karlsruh
germani
cell
fix
ethanol
aceton
cell
permeabil
block
describ
glitscher
et
al
cell
incub
antiflaviviru
group
antigen
antibodi
clone
merck
millipor
darmstadt
germani
progen
biotechnik
gmbh
heidelberg
germani
follow
incub
antimous
iggalexa
thermo
fisher
scientif
waltham
usa
antiguinea
pig
jackson
immunoresearch
west
grove
usa
nuclei
visual
carl
roth
karlsruh
germani
protocol
coverslip
mount
microscop
slide
mowiol
analyz
use
confoc
laser
scan
microscop
lsm
meta
zen
softwar
carl
zeiss
oberkochen
germani
creation
ultrathin
section
cell
seed
cultur
dish
treat
sigmaaldrich
st
loui
usa
h
cell
fix
glutaraldehyd
carl
roth
karlsruh
germani
dmem
complet
min
room
temperatur
afterward
cell
scrap
cultur
dish
warm
agaros
solut
ad
cell
small
agaros
block
contain
cell
cut
postfix
osmium
tetroxid
pb
subsequ
cell
dehydr
increas
ethanol
concentr
embed
liquid
epoxi
resin
resin
incub
h
polymer
cut
ultrathin
section
ultramicrotom
section
fix
glowdischarg
carbonco
nickel
grid
treat
uranyl
acet
min
subsequ
treatment
lead
citrat
min
ultrathin
section
analyz
transmiss
electron
microscop
carl
zeiss
oberkochen
germani
result
describ
mean
standard
deviat
sd
least
independ
experi
signific
result
analyz
student
test
use
graphpad
prism
graphpad
softwar
la
jolla
usa
persaud
et
al
show
acidif
endosom
compart
crucial
entri
strain
wonder
whether
would
differ
strain
respons
caus
mild
symptom
uganda
strain
known
associ
neurolog
complic
investig
cell
pretreat
nm
bafilomycin
two
hour
later
presenc
substanc
cell
infect
use
moi
either
french
polynesia
uganda
strain
analysi
infect
perform
hour
postinfect
hpi
case
cell
also
analyz
hpi
quantif
number
intra
extracellular
viral
genom
rtqpcr
reveal
signific
amount
zikv
rna
strain
figur
b
cell
find
indic
bafilomycin
inhibit
infect
process
quantif
number
intra
extracellular
infecti
particl
via
plaqu
assay
confirm
strain
extrem
low
undetect
amount
intracellular
extracellular
viral
particl
measur
figur
confirm
confoc
laser
scan
microscopi
zikvinfect
cell
use
envelop
proteinspecif
antibodi
contrast
control
zikvposit
cell
observ
treat
bafilomycin
figur
concern
cell
amount
intracellular
extracellular
zikv
rna
significantli
decreas
hpi
bafilomycin
treatment
howev
unlik
still
possibl
detect
consider
amount
viral
rna
figur
b
howev
confoc
laser
scan
microscopi
zikvinfect
cell
reveal
zikvposit
cell
treatment
time
point
analyz
figur
effect
bafilomycin
cell
viabil
cell
investig
determin
metabol
activ
via
prestoblu
assay
minor
reduct
cell
viabil
could
observ
h
treatment
wherea
h
decreas
approxim
figur
e
taken
togeth
data
demonstr
preincub
zikvpermiss
cell
bafilomycin
complet
block
establish
infect
cell
diminish
zikv
infect
cell
moreov
major
differ
observ
two
strain
use
describ
data
show
bafilomycin
prevent
establish
zikv
infect
inhibit
receptormedi
endocytosi
studi
effect
compound
establish
infect
cell
primarili
infect
moi
two
hour
later
subject
bafilomycin
treatment
harvest
analysi
infect
perform
hpi
quantif
amount
intra
extracellular
viral
genom
rtqpcr
show
reduct
amount
zikv
rna
hpi
diminish
even
hpi
strain
figur
b
quantif
number
intracellular
infecti
viral
particl
plaqu
assay
reveal
signific
decreas
strain
howev
consider
amount
infecti
viral
particl
still
detect
hpi
cell
infect
french
polynesia
strain
compar
control
figur
contrast
strong
reduct
amount
releas
infecti
viral
particl
observ
treatment
three
time
point
analyz
strain
figur
f
moreov
confoc
laser
scan
microscopi
show
lower
amount
zikvposit
cell
treat
bafilomycin
comparison
untreat
control
figur
control
whether
observ
effect
bafilomycin
zikvinfect
cell
result
cytotox
metabol
activ
measur
prestoblu
assay
h
treatment
could
slight
reduct
detect
figur
inhibitori
effect
bafilomycin
number
releas
viral
particl
viral
entri
much
pronounc
compar
decreas
metabol
activ
assum
observ
effect
bafilomycin
treatment
viral
life
cycl
due
impact
cellular
viabil
taken
togeth
result
indic
bafilomycin
impair
spread
zikv
inhibit
de
novo
infect
inhibit
releas
infecti
viral
particl
enabl
clear
discrimin
effect
bafilomycin
viral
entri
viral
releas
cell
infect
moi
hpi
treatment
bafilomycin
initi
time
point
almost
cell
infect
reach
peak
shown
figur
infect
treatment
appli
h
cell
lysat
respect
cell
cultur
supernat
harvest
hpi
due
short
durat
treatment
nm
concentr
chosen
experi
ensur
maximum
effect
compound
assay
dmso
includ
vehicl
control
due
high
amount
chemic
util
perform
experi
strain
treatment
bafilomycin
lead
increas
amount
intracellular
viral
genom
number
releas
viral
genom
significantli
reduc
uganda
strain
compar
control
figur
b
quantif
number
intracellular
infecti
viral
particl
reveal
strain
bafilomycin
lead
signific
chang
although
analysi
supernat
unveil
strong
inhibit
releas
viral
particl
figur
investig
effect
bafilomycin
zikv
matur
cell
cultur
supernat
analyz
western
blot
prm
proteinpr
peptid
detect
analysi
cell
cultur
supernat
harvest
hpi
section
figur
f
reveal
pr
peptid
could
detect
infect
cell
treat
bafilomycin
figur
furthermor
amount
intracellular
zikv
prm
slightli
decreas
treatment
figur
moreov
cell
cultur
supernat
harvest
hpi
confirm
result
one
shown
figur
french
polynesia
strain
hardli
detect
amount
pr
peptid
detect
uganda
strain
strong
reduct
amount
pr
peptid
could
observ
figur
regard
amount
intracellular
zikv
prm
signific
chang
visibl
french
polynesia
strain
wherea
uganda
strain
small
accumul
could
observ
bafilomycin
treatment
figur
effect
nm
bafilomycin
cell
viabil
measur
prestoblu
assay
control
specif
observ
result
although
minor
decreas
cell
viabil
detect
treatment
effect
infect
much
pronounc
reduct
figur
studi
investig
cell
howev
fulli
establish
infect
could
accomplish
hpi
quantif
amount
intra
extracellular
zikv
genom
show
consider
reduct
zikv
rna
bafilomycin
treatment
figur
data
show
treatment
zikvinfect
cell
bafilomycin
affect
infect
supernat
investig
whether
loss
infect
zikv
particl
bafilomycin
treatment
due
impair
viral
matur
cell
infect
moi
hpi
treat
furin
inhibitor
known
inhibitor
viral
matur
analysi
infect
perform
hpi
quantif
number
intra
extracellular
viral
rna
rtqpcr
reveal
furin
treatment
affect
number
intra
extracellular
viral
genom
signific
differ
zikv
rna
strain
except
slight
accumul
amount
intracellular
genom
french
polynesia
strain
furin
inhibitor
treatment
figur
b
observ
moreov
number
intra
extracellular
infecti
viral
particl
determin
plaqu
assay
contrast
quantif
viral
genom
signific
decreas
number
intra
extracellular
infecti
viral
particl
observ
strain
furin
inhibitor
treatment
figur
certain
concentr
chosen
treat
cell
cytotox
metabol
activ
differ
concentr
furin
inhibitor
measur
prestoblu
assay
concentr
analyz
affect
cell
viabil
taken
togeth
result
indic
interfer
furin
activ
furin
inhibitor
affect
zikv
matur
sinc
flavivirus
exploit
autophag
machineri
enhanc
infect
bafilomycin
wellknown
autophagi
inhibitor
investig
whether
system
bafilomycin
affect
zikvdepend
induct
autophagi
purpos
cell
subject
preinfect
postinfect
treatment
analysi
infect
amount
autophagi
protein
perform
hpi
western
blot
analysi
time
point
analyz
accumul
protein
could
detect
inhibit
zikv
infect
control
amount
zikv
figur
indic
chosen
concentr
bafilomycin
impact
autophagi
investig
whether
observ
effect
bafilomycin
mainli
due
effect
autophagi
cell
either
treat
mm
autophagi
inhibitor
nm
rapamycin
act
induc
autophagi
number
infect
cell
analyz
confoc
laser
scan
microscopi
use
envelop
proteinspecif
antibodi
fluoresc
microscopi
reveal
modul
autophagi
cell
affect
number
zikvposit
cell
figur
e
data
suggest
observ
effect
bafilomycin
treatment
primarili
due
effect
autophagi
character
relev
compart
cell
treat
treatment
appli
h
infect
cell
accumul
cholesterol
late
endosomesmvb
lysosom
result
inhibit
activ
cell
infect
moi
either
french
polynesia
uganda
strain
infect
analyz
hpi
quantif
number
intra
extracellular
viral
genom
via
rtqpcr
show
signific
reduct
amount
zikv
rna
strain
figur
b
compar
result
obtain
zikvinfect
cell
figur
moreov
effect
confirm
quantif
number
intra
extracellular
infecti
viral
particl
plaqu
assay
infect
cell
subject
treatment
present
significantli
lower
viru
titer
regardless
strain
use
infect
figur
nevertheless
hpi
intracellular
viru
titer
french
polynesia
infect
cell
significantli
differ
cell
possibl
explan
could
time
point
low
product
viral
particl
occur
due
cytopath
effect
infect
untreat
cell
result
releas
viral
particl
dead
cell
cell
infect
attenu
therefor
less
pronounc
cytopath
effect
occur
effect
togeth
contribut
absenc
signific
impact
time
point
control
whether
observ
effect
zikvinfect
cell
specif
due
impair
cellular
viabil
metabol
activ
measur
prestoblu
assay
similar
bafilomycin
h
treatment
could
minor
reduct
detect
figur
sinc
inhibitori
effect
could
alreadi
observ
earlier
time
point
assum
effect
base
cell
toxic
furthermor
effect
zikvinfect
cell
analyz
confoc
laser
scan
microscopi
gradual
accumul
cholesterol
monitor
dye
filipin
complex
bind
free
cholesterol
moreov
impair
lysosom
function
consequ
treatment
verifi
increas
amount
autophagi
substrat
although
antivir
activ
alreadi
visibl
hpi
character
lower
number
zikvposit
cell
treatment
maximum
cholesterol
accumul
observ
hpi
figur
b
addit
sampl
analyz
higher
magnif
investig
whether
treatment
could
influenc
intracellular
local
distribut
e
protein
treatment
evid
chang
subcellular
distribut
amount
cell
envelop
protein
green
signal
could
visual
figur
cell
intens
stain
larg
green
structur
disappear
dispers
stain
could
observ
besid
clear
impact
amount
distribut
structur
protein
e
effect
treatment
amount
nonstructur
protein
investig
western
blot
analysi
amount
reduc
treatment
strain
time
point
investig
especi
pronounc
hpi
accord
rna
data
shown
figur
b
efficaci
treatment
reflect
increas
amount
lysosomeassoci
protein
figur
addit
function
inhibitor
reflect
format
multilamellar
bodi
mlb
lipid
droplet
evidenc
transmiss
electron
microscopi
ultrathin
section
cell
figur
taken
togeth
display
antivir
activ
zikv
result
defect
function
endosom
lysosom
investig
step
viral
life
cycl
affect
cell
pretreat
h
infect
either
moi
presenc
substanc
infect
either
french
polynesia
uganda
strain
analyz
hpi
rtqpcr
quantif
number
intracellular
viral
genom
show
reduct
strain
regardless
amount
viral
input
use
figur
b
moreov
discrimin
whether
decreas
base
impair
viral
entri
viral
replic
cell
subject
condit
describ
analyz
confoc
laser
scan
microscopi
cell
exclus
infect
moi
similar
observ
cell
dispers
zikvenvelop
protein
observ
figur
even
though
signal
intens
envelop
protein
reduc
distribut
envelop
protein
chang
condit
total
number
zikvposit
cell
significantli
affect
figur
corrobor
data
report
gene
assay
perform
zikvrluc
produc
cell
treat
h
cell
luciferas
activ
directli
reflect
genom
replic
report
gene
assay
reveal
signific
decreas
luciferas
activ
cell
figur
addit
western
blot
analys
cellular
lysat
deriv
cell
perform
use
zikv
envelop
zikv
antibodi
blot
correspond
quantif
indic
amount
zikv
zikv
envelop
protein
reduc
cell
figur
g
figur
taken
togeth
data
show
inhibit
zikv
replic
zikv
entri
process
fulli
understood
bafilomycin
wellcharacter
inhibitor
vatpas
frequent
use
restrain
infect
virus
intern
receptormedi
endocytosi
persaud
et
al
demonstr
compound
inhibit
entri
zikv
strain
vero
cell
data
show
bafilomycin
strongli
impair
entri
zikv
uganda
known
caus
mild
symptom
zikv
french
polynesia
associ
neurolog
complic
cell
data
line
previou
observ
describ
ammonium
chlorid
chloroquin
potenti
block
zikv
infect
also
reflect
observ
infect
process
varieti
flavivirus
dengu
viru
west
nile
viru
inhibit
prevent
receptormedi
endocytosi
bafilomycin
ad
postinfect
reduct
number
releas
viral
genom
hpi
complet
inhibit
hpi
howev
amount
releas
infecti
viral
particl
time
point
practic
zero
indic
addit
inhibitori
effect
entri
process
bafilomycin
also
affect
releas
viral
particl
hpi
presenc
viral
genom
supernat
bafilomycin
cell
signific
amount
infecti
viral
particl
suggest
genom
measur
repres
defectiveunprocess
viron
nake
capsidsgenom
observ
inhibitori
effect
experi
seem
contrast
data
publish
cortes
et
al
studi
inhibitori
effect
bafilomycin
treatment
observ
substanc
appli
h
postinfect
howev
concentr
nm
use
studi
could
concentr
requir
effici
inhibit
vatpas
describ
nm
moreov
differ
cell
cultur
model
studi
cortes
et
al
cell
use
might
differ
capac
metabol
xenobiot
inhibitori
effect
bafilomycin
releas
zikv
confirm
fulli
establish
infect
hpi
number
releas
infecti
viral
particl
strongli
decreas
amount
releas
viral
rna
less
affect
reflect
releas
noninfecti
particl
nake
genom
zikvmorphogenesi
process
prm
membran
protein
furinlik
proteas
occur
describ
varieti
flavivirus
chang
ph
tgn
compart
bafilomycin
strongli
impair
activ
enzym
could
affect
conform
chang
requir
proteolyt
process
inde
western
blot
analysi
reveal
format
prpeptid
reflect
process
prm
protein
prevent
bafilomycin
quantif
releas
viral
genom
indic
still
signific
releas
viral
genom
case
cell
treat
nm
bafilomycin
h
harvest
figur
interpret
releas
per
se
strongli
affect
accord
strong
intracellular
accumul
prm
observ
figur
howev
plaqu
assay
data
reveal
infect
releas
particl
strongli
decreas
figur
hypothes
could
due
impair
process
prm
pr
fragment
reflect
western
blot
analysi
shown
figur
specif
observ
effect
control
viabil
assay
show
moder
reduct
metabol
activ
h
decreas
approxim
much
less
pronounc
compar
almost
complet
loss
viral
rna
infecti
viral
particl
data
furin
inhibitor
experi
show
inhibit
furin
activ
lead
reduc
amount
releas
infecti
viral
particl
could
support
hypothesi
note
order
avoid
cytotox
effect
furin
inhibitor
compound
use
concentr
significantli
lower
concentr
requir
complet
inhibit
furin
activ
bafilomycin
known
inhibit
autophagi
investig
whether
interfer
bafilomycin
zikvdepend
induct
autophagi
experiment
system
whether
relev
observ
bafilomycin
effect
describ
inde
observ
impair
zikvdepend
induct
autophagi
howev
modul
autophagi
either
rapamycin
effect
number
infect
cell
suggest
bafilomycindepend
interfer
autophagi
primarili
caus
observ
effect
studi
seem
contrast
studi
describ
direct
effect
autophagi
modul
zikv
life
cycl
experiment
set
includ
incub
period
concentr
differ
studi
gain
insight
relev
compart
intracellular
cholesterol
transport
inhibitor
use
studi
effect
zikv
life
cycl
investig
first
time
prolong
treatment
result
inhibit
function
late
endosomesmvb
lysosom
consequ
accumul
cholesterol
organel
experiment
verifi
increas
number
lipid
droplet
format
nonfunct
lysosom
socal
multilamellar
bodi
mlb
although
could
significantli
diminish
amount
intracellular
extracellular
viral
genom
infecti
viral
particl
time
point
analyz
infect
persist
hpi
nevertheless
hpi
number
intracellular
infecti
viral
particl
french
polynesiainfect
cell
approxim
treat
explain
fact
strain
higher
cytopath
effect
caus
signific
cell
death
hpi
wash
hpi
thu
viru
titer
similar
one
measur
hpi
sinc
treatment
slow
typic
infect
kinet
higher
number
intracellular
infecti
viral
particl
could
detect
persist
zikv
infect
hpi
treatment
could
easili
observ
confoc
laser
scan
microscopi
analysi
zikvposit
cell
still
found
time
point
even
presenc
treatment
number
zikvposit
cell
increas
hpi
find
might
indic
main
effect
viral
replic
howev
experi
could
exclud
complet
compound
minor
effect
viral
entri
moreov
intracellular
local
distribut
zikv
envelop
protein
also
chang
treatment
cell
viral
envelop
protein
found
dispers
throughout
cytoplasm
instead
concentr
dotlik
compart
data
support
possibl
effect
viral
replic
nevertheless
definit
conclus
drawn
experi
sinc
treatment
start
h
infect
cholesterol
accumul
visibl
h
treatment
previous
report
poh
et
al
takano
et
al
clarifi
point
infect
cell
moi
pretreat
h
analyz
rtqpcr
differ
amount
viral
input
led
foldreduct
hpi
suggest
effect
might
viral
replic
find
confirm
confoc
laser
scan
microscopi
consider
number
zikvposit
cell
could
observ
pretreat
analysi
replic
luciferas
report
viru
effect
viral
entri
would
possibl
observ
cell
singl
viral
particl
signific
amount
distribut
envelop
protein
describ
poh
et
trap
dengu
viru
late
endosom
interestingli
flavivirus
hepat
c
viru
elgner
et
al
show
replic
affect
treatment
number
intracellular
viral
genom
amount
remain
constant
also
investig
effect
amount
nonstructur
protein
envelop
protein
western
blot
analysi
show
amount
e
protein
decreas
treatment
data
strongli
point
toward
effect
replic
level
inhibit
traffick
intracellular
cholesterol
accumul
late
endosom
lysosom
repercuss
membran
composit
fluiditi
endoplasm
reticulum
therefor
like
affect
format
replic
complex
report
describ
impact
replic
flavivirus
hcv
denv
although
differ
structur
organ
replic
factori
format
membran
web
structur
seem
parallel
make
access
inhibit
light
fact
nowaday
neither
vaccin
specif
therapi
zikv
exist
substanc
interf
acidif
function
compart
intracellular
transport
cholesterol
could
help
firstlin
treatment
prevent
spread
zikv
infect
epidem
situat
conclud
data
bafilomycin
exert
inhibitori
effect
zikv
life
cycl
interf
entri
releas
process
moreov
conclud
steroid
drug
affect
zikv
life
cycl
inhibit
replic
